文献速递头颈外科

择区性颈清扫在高分级腮腺癌中的作用:基于医院的队列研究

The role of elective neck dissection in high-grade parotid malignancy: A hospital-based cohort study.
PubMed 文献 · Laryngoscope · 2019-08-29

本研究基于美国国家癌症数据库2004至2013年确诊的1547例临床N0高分级腮腺癌患者,评估择区性颈清扫(END)与生存的关联。中位随访48个月,END对3年生存率无统计学显著影响(接受END者69.9%,95%CI 67.2-72.6;未接受者66.1%,95%CI 62.7-69.5)。腮腺切除术和辅助放疗对死亡率影响最强。

要点

  • 在cN0高分级腮腺癌患者中,END未显著改善3年生存率。
  • 腮腺切除术和辅助放疗是对死亡率影响最强的治疗因素。
  • END在各亚组(黏液表皮样癌、腺癌、高风险组织学、高T分期、学术中心)中均无显著生存获益。

核心结论

  • 在考虑辅助治疗和混杂因素后,END对cN0高分级腮腺癌患者的生存无统计学显著影响。
  • END对生存和局部区域控制的作用仍需前瞻性研究进一步阐明。

研究设计与样本

  • 回顾性多中心队列研究,基于美国国家癌症数据库的医院病例。
  • 主要暴露为是否接受颈清扫,次要暴露为是否接受辅助放疗和/或化疗,进行单因素和多因素生存分析。

主要发现

  • 接受END者3年生存率为69.9%(95%CI 67.2-72.6),未接受END者为66.1%(95%CI 62.7-69.5),差异无统计学意义。
  • 腮腺切除术和辅助放疗对死亡率的影响最强。
  • 在接受腮腺切除术和辅助放疗的患者中,按是否接受END分层,3年生存率无差异。
  • END在黏液表皮样癌、腺癌、高风险组织学、高T分期或学术中心治疗亚组中均无统计学显著生存效应。

临床怎么用

  • 对于cN0高分级腮腺癌,END的常规应用需权衡辅助治疗和混杂因素,不应仅基于生存获益决定。
  • 腮腺切除术和辅助放疗是影响生存的重要治疗手段。

局限性

  • 回顾性研究设计,证据等级为4级。
  • 来自摘要,未报告具体混杂因素调整方法和亚组样本量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES/HYPOTHESIS: The role of elective neck dissection (END) in patients with clinically N0 (cN0), high-grade parotid carcinoma is unclear. The objective of this study was to assess the association between END and survival in patients with cN0, high-grade parotid carcinoma. STUDY DESIGN: Retrospective, multicenter cohort study. METHODS: A review of hospital-based cases from the National Cancer Data Base was performed. Participants included patients diagnosed with cN0, high-grade parotid cancer between January 1, 2004 and December 31, 2013. The primary exposure was receipt of neck dissection. Secondary exposures included receipt of adjuvant radiation and/or chemotherapy. Univariate and multivariate survival analyses were performed. Unadjusted and adjusted survival estimates were determined. RESULTS: Overall, 1,547 patients were included, with a median follow-up time of 48 months. END did not have a statistically significant effect on 3-year survival (3-year: 69.9%, 95% confidence interval [CI]: 67.2 to 72.6). Survival at 3-years among those not receiving END was 66.1% (95% CI: 62.7 to 69.5). Parotidectomy and adjuvant radiotherapy had the strongest effect on mortality. There was no difference in 3-year survival among patients who underwent parotidectomy and adjuvant radiation stratified by receipt of END nor did END have a statistically significant effect on survival in mucoepidermoid carcinoma, adenocarcinoma, high-risk histology, high T stage, or academic center treatment subgroups. CONCLUSIONS: END did not have a statistically significant effect on survival among cN0 patients with high-grade parotid cancer when taking into account receipt of adjuvant therapy and confounding. The role of END on survival and locoregional control remains to be further elucidated in prospective studies. LEVEL OF EVIDENCE: 4 Laryngoscope, 130:1487-1495, 2020.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Harbison RA, Gray AJ, Westling T, et al. The role of elective neck dissection in high-grade parotid malignancy: A hospital-based cohort study. Laryngoscope. 2019. PMID: 31468551. doi:10.1002/lary.28238

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。